Edited by Francesco Pezzella and Chao-Nan Qian
Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs approved by the Food & Drug Administration (FDA) of the United States. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue of the Chinese Journal of Cancer (CJC), the world leading experts in pathology, molecular biology, pharmacology, and clinical study have contributed their critical thoughts and insightful investigations from different angles to reveal the alternative tumor angiogenesis approaches and potential treatment targets. This special issue is therefore initiating a new era in tumor angiogenesis research, aiming to develop next-generation anti-angiogenic targeted therapy.
This series was published in Chinese Journal of Cancer.